NORCROSS, Ga.--(BUSINESS WIRE)--Auriga Laboratories, Inc. (OTCBB: ARGA) or "Auriga", a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and Xerostomia, announced today that it has entered into an exclusive license to make, use and sell proprietary products, technology and patents relating to the treatment of the common cold with zinc. The first product, ColdCure zinc lozenges, employ a novel formulation to dramatically reduce the duration and severity of common cold symptoms in two independent, randomized, double-blind, placebo-controlled clinical trials published in peer reviewed medical journals. This unique formulation is protected by nine patents.
